Company profile
REPLIMUNE GROUP, INC.
NASDAQ:REPLBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TUDRIQEV | approved | — | 0 | — |
| NIVOLUMAB | phase2 | — | 222 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06581406 | phase2_3 | recruiting | 2024-12-17 | 2030-01-01 | Replimune, Inc. | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma |
| NCT05733611 | phase2 | terminated | 2023-06-29 | 2025-08-18 | Replimune, Inc. | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC |
| NCT04050436 | phase2 | active_not_recruiting | 2019-10-08 | 2025-09-01 | Replimune, Inc. | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer |
| NCT03767348 | phase2 | active_not_recruiting | 2017-09-20 | 2028-06-01 | Replimune, Inc. | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) |
| NCT04336241 | phase1 | active_not_recruiting | 2019-10-17 | 2026-10-31 | Replimune, Inc. | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125827 | 2026-08-06 | BLA | REPLIMUNE, INC. | |||||
Loading… | ||||||||